EICHOR
Recruiting studies: Locally Advanced Or Metastatic Renal Cell Carcinoma
Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid TumorPhase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Phase 1 · 30 location(s) · Calico Life Sciences LLC · NCT04777994A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer
Phase 2 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06962787EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
Phase N/A · 1 location(s) · AstraZeneca · NCT07024680Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carci
Phase 2 · 3 location(s) · Qian Qin · NCT06794229A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (R
Phase 3 · 38 location(s) · Xynomic Pharmaceuticals, Inc. · NCT03592472An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3
Phase 2 · 1 location(s) · Yonsei University · NCT07469683A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Meta
Phase 1/Phase 2 · 42 location(s) · Inhibrx Biosciences, Inc · NCT04198766Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Hist
Phase 2 · 4 location(s) · Emory University · NCT05756569Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell
Phase 1/Phase 2 · 1 location(s) · University of Michigan Rogel Cancer Center · NCT06866262Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT052676269MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06823427Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica
Phase 1/Phase 2 · 128 location(s) · Pfizer · NCT07227415A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With C
Phase 1 · 41 location(s) · Genentech, Inc. · NCT05581004Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Ce
Phase 1 · 11 location(s) · Neomorph, Inc · NCT07300241A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
Phase 1 · 20 location(s) · HiberCell, Inc. · NCT06234605GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
Phase 1/Phase 2 · 4 location(s) · GeneMedicine Co., Ltd. · NCT06265025Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 · 10 location(s) · Nammi Therapeutics Inc · NCT06582017
Look up another condition
Patient organization or foundation? You can brand
this page for your community — your logo, your resources, same honest
registry data, kept current daily.
Ask about branding →